Primary headache disorders are frequently encountered in the pediatric population. The therapeutic approach consists of a multimodal program, including lifestyle modification, psychotherapeutic intervention, pharmacotherapy, and complementary measures. This systematic review focuses on the pharmacotherapy of pediatric migraine and tension-type headache (TTH). In addition to the general treatment principles, the results of 33 clinical reports published on the topic since 2008 are outlined in detail. Furthermore, a tabular summary of previously investigated agents not studied since 2008 is given, as is an overview of promising pharmacologic approaches so far only evaluated in adults. A variety of pharmacologic options is available, but high-quality evidence is limited to single agents. At this time, approval is restricted to four triptans and flupirtine for the symptomatic treatment of pediatric acute migraine and TTH, respectively. No agent has been approved for the prevention of pediatric primary headaches. This review does not grade the drugs hierarchically because the complex profiles of many agents differ only slightly or even overlap. However, a detailed expert opinion is provided. On the basis of the outlined facts, the team of physician, patient, and parents has to decide on the most appropriate regimen for the individual situation in the sense of personalized medicine.

Keywords
► migraine
► tension-type headache
► acute headache treatment
► preventive headache treatment
► prophylactic headache treatment
► pediatrics
headache disorder in children and adolescents is assigned in accordance to the classification established by the International Headache Society (IHS). On the basis of these criteria, 7 to 10% of children and adolescents are considered to suffer migraine, up to 15% probable migraine, and 20 to 25% tension-type headache (TTH). The reported 6-month prevalence of migraine or TTH in German grammar students is 10.2 and 48.7%, respectively. Some 19.8% of the studied population experience a combination of migraine and TTH, commonly encountered as mixed-type headache in the pediatric population.

Therapeutic approach consists of a multimodal program of pharmacotherapy, life-style intervention, psychoeducation, biobehavioral, and psychotherapeutic strategies as well as complementary measures individually composed for each patient. The range of applied interventions depends on the degree of disability and impairment of quality of life attributed to the headache as well as their availability. A variety of pharmacotherapeutic options have been established for the treatment of adult primary headaches. However, agreement on the pharmacologic strategy in children and adolescents is a particular challenge, because appropriate safety and efficacy data of many of those agents are limited or even missing for the pediatric population. In 2008, the German Migraine and Headache Society and the Society for Neuropediatrics published revised, evidence-based recommendations for the treatment of primary headache disorders in childhood (German National Guideline [GNG] 2008).

The aim of this literature review is to provide an update on recent advances in pharmacotherapy of pediatric migraine and TTH since the publication of GNG 2008. Therefore, the literature concerning the topic published during the past 5 years was systematically reviewed. Given the wide range of drugs and their (in many cases) overlapping or only slightly varying profiles, this review does not grade the drugs hierarchically. On the basis of the outlined facts, the team of physician, patient, and parents needs to decide on the most appropriate regimen for the individual situation in the sense of personalized medicine. Complementary and biobehavioral treatment strategies are not the subject of this review.

Methods

MEDLINE and Cochrane Library were systematically searched for articles dealing with the treatment of pediatric headache published from January 2008 through June 2012. The following search commands were applied: pediatric AND headache treatment, acute or prevention or prophylactic treatment AND pediatric headache, migraine or tension-type headache AND treatment AND pediatric, migraine or tension-type headache AND prophylaxis AND pediatric. The language filter was set to English and German publications. The identified 587 titles and abstracts were reviewed for content and relevance to select those covering pharmacologic aspects of pediatric primary headache. In addition, checking the reference lists of the selected 68 articles for pertinent articles completed the bibliography. In total, 77 articles dealing with the subject of this update were reviewed in detail.

Articles were included to the bibliography if they fulfilled the following criteria:

1. Systematic review (n = 8); review (n = 27); clinical report (n = 33); (randomized) controlled trial, uncontrolled trial, retrospective study or case report; report on pharmacokinetics (n = 1); report on clinical practice (n = 8).
2. Published between January 1, 2008, and June 30, 2012. The starting date was chosen to tie up to GNG 2008; June 2012 was the last full month before finalizing this review.
3. Reporting on a pediatric population suffering migraine or TTH.
4. The diagnosis of primary headache disorder was based on the IHS classification of 2004.
5. Reporting on pharmacotherapy of migraine or TTH.

Data collected from the clinical reports included (1) study design, (2) drug reported, (3) dosing and duration of medication, (4) efficacy and adverse events of medication, (5) indication reported on, (6) age group treated, (7) number of participants, (8) inclusion and exclusion criteria, (9) end points, and (10) statistical method used. We conducted the literature search, data collection, and analysis of the articles dealing with the update subject according to the principles of evidence-based medicine postulated by the Cochrane Collaboration. In addition to the outlined pediatric literature, the most recent guidelines and publications on future directions in treating adult primary headaches have been studied.

Current Information

Treatment Principles

In migraine attacks a fast reactive therapeutic approach is indicated. Acute therapy aims to relieve the symptoms as fast as possible to enable the patient to return to normal function within 1 to 2 hours without risk of relapse. In acute episodes of TTH a more defensive strategy is appropriate, as participation is usually not interrupted. The chosen medication has to ensure the most consistent response and the least side effects possible. To guarantee an optimized effect the patient must have quick access to the medication in any place and has to be thoroughly advised in the treatment strategy and application practice. Detailed clues for the symptomatic treatment in different settings are shown in Tables 1–3.

Preventive therapy is indicated for patients suffering frequent migraine (> 1 to 2 per week or > 3 to 4 per month) or experiencing headache-related disability that interferes with school attendance, daily routine, and daily activities (e.g., PesMDAS > 30). Prophylaxis should also be considered if acute treatment options are ineffective, not tolerated, contraindicated, or regularly overused and in patients prone to extremely intensive, prolonged (> 48 hours), hemiplegic, or basilar-type migraine or severe aura. Prophylaxis can be appropriate in patients prone to frequent episodic TTH and should be discussed in patients suffering chronic TTH (CTTH). In general, pharmacologic prophylaxis is only
indicated if lifestyle modification and nonpharmacologic measures have been ineffective. Detailed clues for preventive treatment are displayed in Table 4.

Every physician taking care of pediatric headache patients should be familiar with some key features of the pharmacologic treatment, as displayed in Fig. 1.

### Symptomatic Treatment of Acute Episodes of Migraine and Tension-Type Headache

#### Analgesics and Nonsteroidal Anti-inflammatory Drugs

Concerning analgesic and anti-inflammatory treatment of headaches with analgesics and nonsteroidal anti-inflammatory drugs:

<table>
<thead>
<tr>
<th>Goals: fast relief of pain, return to normal activity, no relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Take drug rapidly after onset (within 30 min)</td>
</tr>
<tr>
<td>Dose adequately high for age and weight</td>
</tr>
<tr>
<td>Repeat after 3–4 hours if necessary</td>
</tr>
<tr>
<td>Do not exceed three times intake a week</td>
</tr>
</tbody>
</table>

#### Table 1

### Table 2

#### Goals: fast relief of pain and associated symptoms, return to normal activity, no relapse, no progress of peripheral to central sensitization

<table>
<thead>
<tr>
<th>Consider different formulations (e.g., nasal spray, orally disintegrating tablet) in line with associated symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclude contraindications for triptans before prescription: vascular conditions (e.g., stroke, transient ischemic attack, hypertension, angina pectoris, myocardial infarction, peripheral artery occlusive disease, Raynaud syndrome), presence of vascular risk factors, intake of monoamine oxidase inhibitors (within 2 weeks) or ergotamines, impaired renal or liver function, pregnancy and lactation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Do not generalize the whole triptan group: if one triptan does not show efficacy in a patient (≥3 unresponsive episodes), try another as small differences in pharmacokinetic properties can be of clinical importance</th>
</tr>
</thead>
</table>
| Two different triptan models:
  - Rescue strategy: start with an NSAID in adequate dose at headache onset, use the triptan if relief is insufficient |
  - Stratified strategy: determine severity at headache onset, take NSAIDs or triptan if severity surpasses the individually determined triptan threshold (preferred by the authors) |

<table>
<thead>
<tr>
<th>Repeat no more than once not before 2 hours after first dose and only if first dose did have an effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not exceed intake two times per week and six times per month</td>
</tr>
</tbody>
</table>

#### Table 3

| Patients prone to aura must not use triptans as long as aura symptoms are present but only if aura has dissolved and headache starts |

**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.

**a**In case of insufficient experience in handling triptans, referral to a specialized center is indicated.

### Table 4

#### Analgesic Treatment of Acute Episodic Migraine

- Acetylsalicylic acid: pseudoallergic asthma, gastrointestinal ulceration, impaired coagulation, heart failure, renal or liver failure, pregnancy; cave: febrile conditions in pediatric patients (Reye syndrome)
- Dopamine antagonists: extrapyramidal symptoms, epilepsy, prolactinoma, phaeochromocytoma, pregnancy
- Dihydroergotamine: see triptans + migraine of basilar or familiar hemiplegic type, vasculitis, porphyria, treatment with macrolid antibiotics, several HIV medications, azol-type mycotics or vasoconstrictors (including triptans!)
- Valproate: impaired hepatic or pancreatic function, hepatic disease (family anamnesis!), fatal liver failure in family, porphyria, impaired coagulation, insulin-dependin diabetes
- Consider admission if parenteral “rescue” is necessary
- In any case, patients treated with parenteral dihydroergotamine should be admitted
- Discuss probability of headache recurrence with patients before discharge
- Educate patients in self-medication in case of recurrence
- Preventive medication with NSAIDs or steroids over the following days has not been established in pediatrics so far

**Abbreviations:** HIV, human immunodeficiency virus; NSAIDs, nonsteroidal anti-inflammatory drugs.

**a**Emergent treatment of exacerbated migraine should be reserved for experienced specialists.

**b**The most relevant contraindications are listed.
Table 4: Detailed clues for the preventive treatment of headaches

Goals:
- Reduction in headache severity parameters as set individually with the patient
  - Migraine: i.e., frequency < 1–2/month; PedMIDAS < 10 (reflecting reduced disability and interference with daily activities)
  - FTTH, CTTH: i.e., significant reduction of frequency and intensity of headaches
  - CDH: i.e., intensity of every day headache < 5 on the visual pain scale
- Reduction in frequency of use of acute treatment (avoidance of chronic overuse)
- Reduction in headache-related distress and psychological manifestations
- Improvement of overall quality of life (assessed by PedsQL)

Preventive regimen:
- Choose drug with regard to the patient’s clinical features, comorbidities, and drug profiles
- Start at a low dose
- Titrate slowly over 4 (to 12) weeks
- If a trend of improvement is seen, adjust dose for optimal control
- If sustained, satisfying response is achieved, continue therapy for 4–6 months
- Wean slowly (not during stressful times, prefer vacations)

Problems:
- Onset of improvement is often delayed in children and adolescents: do not give up too early and educate patients on importance of adherence
- Incompliance is associated with poor response, higher risk of side effects, and worse overall prognosis
- Drug resistance is possible: if no or insufficient response is achieved after 12 weeks, switch to another agent; failure of one agent does not predict failure or success with any other

Abbreviations: CDH, chronic daily headache; CTTH, chronic tension-type headache; FTTH, frequent episodic tension-type headache; PedMIDAS, pediatric migraine disability score.
Almotriptan. GNG 2008 graded almotriptan (12.5 mg) as an alternative of third choice in migraine treatment due to limited evidence. Since then, important evidence concerning efficacy and safety in adolescent migraineurs emerged as Linder et al published their randomized, placebo-controlled, multicenter trial in 2008. Analyzing the data of 714 adolescents, this trial demonstrated almotriptan (6.25, 12.5, and 25 mg) to be superior to placebo in regard to pain relief and pain freedom after 2 hours and sustained pain relief up to 24 hours. Findings were especially marked in the subgroup of 15- to 17-year-old adolescents. In the subgroup of 12- to 14-year-old patients, significance was not reached because of a higher placebo response rate. In addition, a significant improvement of photo- and phonophobia 2 hours after dosing was observed with 12.5-mg almotriptan but not with the two other doses. In general, almotriptan was well tolerated. These findings support the use of almotriptan in adolescent migraineurs, particularly at a dose of 12.5 mg associated with the best efficacy profile. Based on these results, in 2009, the U.S. Food and Drug Administration (FDA) approved oral almotriptan (6.25 and 12.5 mg) for the treatment of migraine in adolescents (≥12 years) suffering severe migraine attacks (≥4 hours duration). The first triptan approved by the FDA for adolescents, currently almotriptan is rated a safe and effective treatment option for adolescents.

Rizatriptan. Rizatriptan was one of the first oral triptans proven effective and safe in pediatric (aged ≥6 years) migraine based on the trial of Ahonen et al in 2006. However, because of inconsistent data from two previous trials, GNG 2008 classified rizatriptan (5 and 10 mg) as an option of third choice in the treatment of pediatric migraine. Possible factors explaining the deviating results of the two other trials were a high placebo response rate, underdosing, population heterogeneity, and inadequate methods of efficiency assessment. In 2009, Ho et al launched a randomized, placebo-controlled, multicenter trial with a double-blind, placebo, run-in design and a weight-based dosing regimen in line with the most recent pharmacokinetic findings stratified to minimize the cited confounders. Recently, the results of this trial were published: In 702 patients aged 12 to 17 years, rizatriptan was significantly superior to placebo in aborting pain, relieving pain (two grades on a five-face pain scale), and ensuring return to “normal function” within 2 hours after treatment as well as sustaining pain freedom up to 48 hours and aborting or preventing nausea or vomiting at the 2-hour time point. Even data concerning photo- and phonophobia at 2 hours after treatment and subjective satisfaction with medication favored rizatriptan without reaching significance. In 275 children aged 6 to 11 years, consistent findings were achieved in all aspects besides aborting or preventing vomiting. However, due to the limited sample size and statistical power, significance was not reached in this subgroup. In all age groups rizatriptan was well tolerated, and the rate of adverse events was similar in the rizatriptan and placebo groups. Based on this trial, the FDA approved rizatriptan oral tablets and orally disintegrating tablets (5 and 10 mg) for the acute treatment of migraine in children 6 years and older in December 2011.

Sumatriptan. Sumatriptan nasal spray (10 mg) was the first triptan approved by the European Medicines Agency (EMA) in 2003 for the treatment of adolescent migraine. GNG 2008 graded sumatriptan nasal spray (10 and 20 mg) as the triptan of first choice for adolescents unresponsive to first-line over-the-counter drugs. In individual case use in younger children has been admitted, as studies have shown effectiveness and safety of nasal sumatriptan also in younger children (≥5 years old). In recent years, no further trials evaluating nasal sumatriptan in pediatric migraine have been reported. Nevertheless, two recent case reports and one case series of children suffering periodic syndromes showed a good...
Table 5 Symptomatic and prophylactic drugs for pediatric primary headaches not addressed in clinical reports since 2008\(^1\)\(^4\)\(^3\)\(^8\)\(^6\)\(^7\)\(^7\)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Evidence/drug profile/comments</th>
<th>German National Guideline 2008 (GNG)(^1)(^4)</th>
<th>Authors’ comments (A)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analgesics and NSAIDs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nimesulide (2.5 mg/kg)</td>
<td>1 RDBCO (N = 66)(^7)(^8): as effective as PCM in pain relief; most widely spread NSAID in some European countries (Italy, France, Greece)</td>
<td>GNG: Not reported;</td>
<td>A: No advantage compared with other NSAID; risk of hepatotoxicity in self-medication patients</td>
</tr>
<tr>
<td>Flupirtine (6–8 yr: 50 mg; 9–12 yr: 100 mg)</td>
<td>1 RDBCO (N = 30): in TTH as effective as PCM; potent and safe agent in acute and chronic pain states in adults; central acting analgesic with normalizing effect on muscle tone</td>
<td>GNG: Alternative to analgesics in TTH patients;</td>
<td>A: Alternative in TTH patients, if NSAID and PCM not efficacious or contraindicated</td>
</tr>
</tbody>
</table>
| ASS (≤ 12 yr: 10 mg/kg; 25 mg/kg/d; ≥ 12 yr: 500–1,000 mg) | 1 RDBPC (N = 63)\(^4\)^: Effective and safe in TTH patients > 15 yr; first-line option in adults; generally not recommended ≤ 12 yr due to possible risk of Reye syndrome | GNG: Treatment of further choice in adolescents; | A: Alternative in adolescents: cave: Reye syndrome (ongoing controversy as a defined cause-effect relationship is not supported by sufficient data\(^2\)^)

| **Migraine-specific drugs** | | | |
| Eletriptan (20 mg; 40-mg oral tablet) | 1 RDBPC (N = 274): Not superior to placebo in pain relief, significantly lower 24-hr recurrence rate, well tolerated; alternative triptan in adults, fast onset of action (within 30 min) | GNG: Not rated due to limited evidence; | A: Further pediatric data needed |
| Naratriptan (2.5-mg oral tablet) | 1 RDBPC (N = 300); 1 ibuprofen-controlled trial (N = 40) (only abstract available)\(^1\)^: not superior to placebo, better pain relief than ibuprofen, similar tolerability; alternative triptan in adult migraine; onset of action later than other triptans (up to 4 hr), lesser side effects | GNG: Not rated due to limited evidence; | A: Further pediatric data needed |
| Sumatriptan oral (50 mg, 100 mg) | 1 RDBPCCO (N = 23): Not superior to placebo in pain relief; first-line triptan in adults, onset of action within 60 min; no difference in efficacy to nasal spray or suppositories | GNG: Not rated due to limited evidence; | A: Further pediatric data needed |
| DHE oral (20–40 µg/kg) | 1 RDBPCCO (N = 12): Better responder rate in DHE (2 doses) than placebo (not significant); recurrence rate 2/5; in adults option of further choice as there is no advantage compared with triptans, worse tolerability than triptans, high risk of rebound headache and risk of abuse | GNG: Alternative of further choice; | A: Oral administration is of limited value due to interference with migraine and DHE associated nausea |

| **Oral antiemetics** | | | |
| Dimenhydrinate (1–2 mg/kg) | No trials; relevant side effect: sedation | GNG: No pediatric data available; all agents are possible options; patients suffering gastrointestinal symptoms; | A: Patients suffering disabling nausea or refusing intake of drugs due to nausea can profit of antiemetics; |
| Domperidone (1 mg/kg) | No trials; reasonable in patients with gastroparesis, may lead to increased absorption of drugs; relevant side effect: extrapyramidal symptoms | GNG: Patients suffering disabling nausea or refusing intake of drugs due to nausea can profit of antiemetics; | A: Patients suffering disabling nausea or refusing intake of drugs due to nausea can profit of antiemetics; |
| Metoclopramide (0.1–0.2 mg/kg) | No trials; good efficacy and tolerability profile of ondansetron, but potential interaction with PCM to be considered (reduced efficacy of PCM); relevant side effect: dizziness, sedation | GNG: Patients suffering disabling nausea or refusing intake of drugs due to nausea can profit of antiemetics; | A: Patients suffering disabling nausea or refusing intake of drugs due to nausea can profit of antiemetics; |

| **Emergency treatment** | | | |
| Ketorolac IV (0.5 mg/kg, max. 30 mg) | 1 RDB (N = 62)\(^2\)^: 55% responder rate, recurrence 30%; NSAID | GNG: Not reported; | A: To be considered in acute migraine and TTH unresponsive to over-the-counter analgesics |
| Sumatriptan SC (0.05–0.2 mg/kg; max. 6 mg) | 2 OLCS (N = 50; 17): possibly effective and safe option; onset of action within 10 min but more side effects compared with other sumatriptan formulations | GNG: Alternative in severe migraine attacks; | A: Orally disintegrating tablets preferred, needle-free device possible future option (Sumavel) |

| **Prophylaxis** | | | |
| Levetiracetam (20–40 mg/kg) | Migraine: 1 OLCS (N = 20); 1 RCR (N = 19): up to 90% responder rate; side effects in 15% of patients; not effective in adults | GNG: Not rated due to limited evidence; | A: Not reasonable (inefficacy in adults, side effects) |
| Zonisamide (3–10 mg/kg) | Chronic headache: 1 RCR (N = 12): responder rate 87.5%; promising results in adult migraine, confirmation needed | GNG: Not rated due to limited evidence; | A: Further pediatric data needed |
| ASS (2–3 mg/kg) | Migraine: 1 RDB (N = 30): as effective as flunarizine; second line in adult migraine; relevant side effect: increased risk of bleeding; generally not recommended ≤ 12 yr due to possible risk of Reye syndrome | GNG: Second-line option with respect to contraindications; | A: Alternative in adolescents: cave: side effects (ongoing controversy on Reye syndrome as a defined cause-effect relationship is not supported by sufficient data\(^2\)^) |
| Pizotifen (0.5–0.75 mg) | Migraine: 1 RDBPCCO (N = 47)\(^4\)^: no significant difference to placebo | GNG: Not reported; | A: Not recommended |

**Not effective in pediatric or adult preventive trials**

- Clonidine, fluoxetine, nimodipine, trazadone, 5-hydroxy-tryptophan, papaverine\(^1\)

GNG: Not recommended; A: Not recommended

---

Abbreviations: ASS, acetylsalicylic acid; DHE, dihydroergotamine; IV, intravenous; kg, kilogram body weight; NSAIDs, nonsteroidal anti-inflammatory drugs; OLCS, open-label case series; PCM, paracetamol; RCR, retrospective chart review; RDB, randomized double-blind trial; RDBCO, randomized, double-blind, crossover trial; RDBPC, randomized, double-blind, placebo-controlled trial; RDBPCCO, randomized, double-blind, placebo-controlled, crossover trial; SC, subcutaneous; TTH, tension-type headache.

\(^1\)If not differently indicated, the listed trials have been cited in GNG 2008.
Table 6 Selection of drugs only established or evaluated in adults so far for the acute and preventative treatment of primary headaches

<table>
<thead>
<tr>
<th>Drug (adult dose)</th>
<th>Drug profile</th>
<th>Adult recommendations</th>
<th>Authors’ comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analgesics and NSAIDs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naproxen sodium (250–500 mg)</td>
<td>Effective pain relief, time to peak level 60 min, half-life &gt; 12 hr</td>
<td>Alternative in acute migraine and TTH</td>
<td>Reasonable alternative in adolescents due to overall profile</td>
</tr>
<tr>
<td>Diclofenac potassium water-soluble powder formulation (50 mg)</td>
<td>In migraine superior to placebo and diclofenac tablets in pain relief; time to peak plasma level 15 min; fast pain relief within 30 min; sustained effect up to 24 hr</td>
<td>No report on powder formulation; diclofenac (oral tablet) is a first-line option for TTH</td>
<td>Promising option, to be considered in adolescents with migraine and TTH due to overall profile</td>
</tr>
<tr>
<td>Combination of paracetamol + caffeine (1,000 + 130 mg)</td>
<td>In TTH superior to placebo and paracetamol monotherapy; direct and adjuvant analgesic effects of caffeine are discussed</td>
<td>First-line option for acute TTH</td>
<td>Possible option in adolescents ≥ 16 yr</td>
</tr>
<tr>
<td><strong>Migraine-specific drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frovatriptan (2.5-mg oral tablet)</td>
<td>One pharmacokinetics and tolerability study in adolescents demonstrated similar profile to adults; probably no dosage adjustment necessary; late onset of action (up to after 4 hr), fewer side effects than other triptans</td>
<td>Alternative in acute migraine</td>
<td>Further pediatric data needed</td>
</tr>
<tr>
<td>Sumatriptan transdermal patch (Zelrix)</td>
<td>Delivery of consistent triptan plasma levels over 4 hr, independently of gastrointestinal symptoms</td>
<td>Not reported; expensive option</td>
<td>Interesting option, pediatric data needed</td>
</tr>
<tr>
<td>DHE oral inhalation (Levadex)</td>
<td>Outpatient use, fast onset of action, sustained effect, good tolerability</td>
<td>Not reported</td>
<td>Interesting option for nonresponders to triptans, pediatric data needed, cave: side effects, abuse</td>
</tr>
<tr>
<td>Calcitonin gene–related peptide antagonists</td>
<td>Further research on telcagepant suspended due to risk of hepatic toxicity; other research compounds currently studied; not available on the market yet</td>
<td>Not rated yet</td>
<td>Pediatric data needed if approved for adults</td>
</tr>
<tr>
<td><strong>Emergency treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASS IV (1,000 mg)</td>
<td>Fast onset of action, high efficacy, good tolerability; generally not recommended &lt; 12 yr due to possible risk of Reye syndrome</td>
<td>First-line option in emergency setting of acute migraine</td>
<td>Consider as option in adolescent migraineurs; cave: Reye syndrome (ongoing controversy as a defined cause–effect relationship is not supported by sufficient data)</td>
</tr>
<tr>
<td>Metamizole IV (1,000 mg)</td>
<td>Effective in aborting acute migraine; relevant side effects; hypotension, agranulocytosis</td>
<td>Alternative in emergency setting of acute migraine</td>
<td>Consider as option in adolescent migraineurs</td>
</tr>
<tr>
<td>Dexamethasone (10 mg) Prednisone (50–100 mg)</td>
<td>Possibly effective in status migrainosus and for prevention of recurrence after exacerbated migraine attacks</td>
<td>Expert consensus favors use of steroids, despite inconsistent data</td>
<td>Pediatric data needed</td>
</tr>
<tr>
<td><strong>Prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gabapentin (900–2,400 mg)</td>
<td>Advantage: fast titration possible, benefit in severely disabled patients with migraine and TTH</td>
<td>Second line in adult migraine Further choice in adult TTH</td>
<td>Pediatric data needed</td>
</tr>
<tr>
<td>Mirtazapine (15–30 mg)</td>
<td>Specific noradrenergic and serotonin-ergic antidepressant</td>
<td>First line in adult TTH</td>
<td>Pediatric data needed</td>
</tr>
<tr>
<td>Tizanidine (4–16 mg)</td>
<td>Central acting muscle relaxant, reasonable in patients with tenderness of pericranial muscles</td>
<td>First line in adult TTH</td>
<td>Pediatric data needed</td>
</tr>
</tbody>
</table>

Abbreviations: ASS, acetylsalicylic acid; DHE, dihydroergotamine; IV, intravenous; NSAIDs, nonsteroidal anti-inflammatory drugs; TTH, tension-type headache.

The authors consider these approaches as possible (future) pharmacologic options in pediatrics.
response to intranasal sumatriptan.\textsuperscript{32–34} Regarding oral administration, up to 2008 efficacy could not be proven and there are no new data available.\textsuperscript{14,28} (\textit{Table 5}).

\textbf{Zolmitriptan.} GNG 2008 rated zolmitriptan orally disintegrating tablet (2.5 mg) and nasal spray (5 mg) as a drug of third choice for the treatment of pediatric migraine.\textsuperscript{14} Since then no novel data have been published, but zolmitriptan nasal spray (2.5 and 5 mg) has been approved by the EMA in 2009 for treating acute migraine episodes in adolescents (≥ 12 years). This approval was based on the results of a randomized, placebo-controlled, crossover, multicenter trial by Lewis et al published in 2007.\textsuperscript{18,20}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|}
\hline
Reference & Indication & Drug (dosage) & Study design, number of patients (N), age of patients, and study period (SP) \\
\hline
29 & M & Almotriptan (6.25, 12.25, 25 mg) & RDBPC; N = 866 (R), 714 (ITT); 12–17 yr; SP: 1 migraine attack \\
\hline
27 & M & Rizatriptan (< 40 kg: 5 mg; ≥ 40 kg: 10 mg) & RDBPC; N = 1382 (R), 977 (ITT); 6–17 yr; SP: 1 migraine attack \\
\hline
33 & AM & Nasal sumatriptan (20 mg) & CR; N = 2; 9, 12 yr \\
\hline
32 & CVS & Nasal sumatriptan (20 mg) & CR; N = 1; 14 yr \\
\hline
34 & CVS & Nasal sumatriptan (20 mg) & OLCS; N = 5 (6 attacks of CVS); 4–24 yr \\
\hline
36 & M & Sumatriptan + naproxen (10/60; 30/180; 85/500 mg) & RDBPC; N = 656 (R), 490 (ITT); 12–17 yr; SP: 1 migraine attack \\
\hline
37 & M & Sumatriptan + naproxen (85/500 mg) & OL; N = 656 (enrolled), 591 (ITT); 12–17 yr; SP: 12 mo \\
\hline
47 & CVS & Subcutaneous sumatriptan (1–3 mg) & OLCS; N = 11 (35 attacks of CVS); 4–24 yr \\
\hline
48 & SM & Metoclopramide/chlorpromazine (not specified) & RCR; N = 184 (187 events); 8–17 yr \\
\hline
49 & SM & Prochlorperazine (0.15 mg/kg; max. 10 mg) & RCR; N = 92 episodes of migraine; 7–17 yr \\
\hline
50 & ACM & Prochlorperazine (5–10 mg) & CR; N = 2 (6 episodes); 11, 16 yr \\
\hline
51 & SM & Prochlorperazine/mectoclopramide + ketorolac (not specified) & RCR; N = 297; age not specified \\
\hline
52 & ACM & Valproate (20 mg/kg) & CR; N = 1; 12 yr \\
\hline
\end{tabular}
\caption{Symptomatic drugs for the acute treatment of pediatric primary headaches addressed in clinical reports since 2008}
\end{table}

\textit{Combination of a Triptan and an Analgesic/NSAIDs or Prokinetic}

In some patients, the goal of consistent, complete, and rapid relief of migraine attacks is not achieved with monotherapy of any type. In those patients, combination therapy may be reasonable.\textsuperscript{20} First, a significant benefit may be achieved in combining drugs with different pharmacodynamics, as migraine is a condition with several pathophysiologic traits. Second, combinations could target associated migraine symptoms, and, third, lower doses of each agent may be sufficient due to synergistic effects.\textsuperscript{26} Hence, in adults this approach is regarded as a reasonable treatment option shown to be effective and safe in various trials.\textsuperscript{18} Different combinations are established (e.g., triptan + NSAID, triptan + prokinetic), and some are already available in fixed formulations (e.g., sumatriptan plus naproxen).\textsuperscript{35} At this time pediatric evidence is limited to data for the combination of sumatriptan with naproxen in adolescents (\textit{Table 7}).

\textbf{Sumatriptan combined with naproxen (suma/nap).} By treating adult migraine with suma/nap better results can be yielded concerning superior efficacy, enhanced medication satisfaction, and improved quality of life compared with its components’ monotherapy.\textsuperscript{36} Recently Derosier et al published the results of their large, randomized, placebo-controlled, multicenter trial dealing with the efficacy and safety of suma/nap in adolescents. Data from 490 patients randomized to placebo or one of three different combination
dosages (10/60, 30/180, and 85/500 mg) are provided. All dosages demonstrated superior efficacy to placebo in 2-hour pain-free rates without differences between the dosing subgroups. The 85/500 dosing was superior to placebo in sustaining pain freedom and in photo- and phonophobia freedom at 2 hours. Additionally, all secondary end points apart from pain freedom at 1 hour and nausea freedom at 2 hours favored the combination over placebo. Numerically, the other doses showed similar trends, except for nausea at 2 hours, where only the lowest dose showed a significantly better response rate than placebo. In 12- to 14-year-old patients 10/60 mg dosing tended to faster pain relief and better overall efficacy, whereas 85/500 mg dosing showed comparable or numerically higher response rates in 15- to 17-year-old adolescents. However, the maximum dose was more frequently related to nausea, particularly in 12- to 14-year-old migraineurs, leading to lower satisfaction with side effects. The high dosing tended to better efficacy at later time points compared with the lower doses. Generally, all three doses were safe and well tolerated. In summary, suma/nap 10/60 mg seems appropriate for younger patients and patients with brief episodes, whereas 85/500 mg seems more appropriate for older patients and patients suffering long-lasting episodes or those at risk of recurrence.

Concerning long-term effects of suma/nap, McDonald et al confirmed a good tolerability profile, a high grade of satisfaction with the treatment regimen, and positive effects on the quality of life in 591 adolescents. Overall, pain freedom within 2 hours was reported in 42% of the treated episodes.

Authors’ Comments on Triptans
Currently, oral almotriptan and rizatriptan and nasal sumatriptan and zolmitriptan are proven effective and safe options in treating pediatric migraine. For oral eletriptan, naratriptan, and sumatriptan no new data have been published since 2008, and for frovatriptan pediatric data are missing at all. Selection of the specific triptan depends on the individual setting. Eletriptan and rizatriptan exert their effects after 30 minutes, almotriptan or oral zolmitriptan after 45 to 60 minutes, and naratriptan or frovatriptan in up to 4 hours. Nasal formulations are supposed to act faster than their oral analogues. Regarding pain relief after 2 hours in adults, eletriptan is the most effective triptan, followed by rizatriptan, followed by oral almotriptan, sumatriptan, and zolmitriptan. Naratriptan and frovatriptan are inferior to oral sumatriptan in this outcome measure but similarly effective after 4 hours. On the other hand, eletriptan tends to cause more side effects than the other triptans, whereas naratriptan and frovatriptan are reported to be better tolerated than sumatriptan. Moreover, triptan profiles differ in recurrence rates (15 to 40%) depending on half-life. Regarding formulations, the use of oral tablets might be limited if gastrointestinal or nausea or vomiting are associated symptoms. Disintegrating tablets are likely to be better accepted by those patients, but a benefit concerning speed of onset does not exist. Intranasal applications are another alternative, but some patients refuse to use them due to a displeasing sensation and disturbance of taste. A novel transdermal patch technique may be a convenient, but so far expensive, option in the future.

Several patients may benefit from combining triptans with NSAIDs or prokinetics as an enhanced overall outcome and satisfaction by offering a logical and optimal timed combination is expected.

Other than sumatriptan and naproxen, the combination of rizatriptan (fast onset of action) with naproxen (sustained effect) seems reasonable.

Migraine-Specific Treatment Options other than Triptans
Regarding orally administered dihydroergotamine (DHE) no new trials have been reported. For alternative DHE formulations so far no pediatric-specific data have been published, as for the group of calcitonin gene–related peptide antagonists currently investigated in adults.

Adjuvant Antiemetics
Currently, no novel pediatric data on the coadministration of oral antiemetics have been published.

Emergency Treatment of Acute Episodes of Migraine and Tension-Type Headache
Acute headache is often (between 1 and 3% of visits) encountered in pediatric emergency departments (EDs). In about 40 to 60% a first episode or exacerbation of primary headache accounts for the visit, with up to 70 and 20% due to migraine and TTH, respectively. Because of the limited data available on pediatric emergent treatment, no definitive recommendations could be given in 2008. Until recently exacerbated migraine has rarely been addressed in pediatric controlled trials, and exacerbated TTH has not been investigated at all. Novel data are available on parenteral dopamine antagonists and DHE for exacerbated migraine, subcutaneous sumatriptan for severe cyclic vomiting syndrome (CVS), and one case report of valproate (VPA) in confusional migraine. Agents not addressed in clinical reports since 2008 are listed in Table 5.

Analygesics. Next to the oral outpatient options for patients still naive to them, parenteral analgesics are a commonly chosen option. Of the available drugs only the NSAID ketorolac was studied in the past. No pediatric efficacy data are available on other parenteral analgesics, including acetylsalicylic acid and metamizole. (Parenteral) opioids should not be administered to pediatric migraineurs because they are inferior to migraine-specific agents and of limited benefit in adults.

Triptans. In patients naive to triptans, these are the first-line option next to analgesics in the emergency setting. In adults subcutaneous sumatriptan is one of the first-line strategies. GNG 2008 graded subcutaneous sumatriptan as an option for status migrainosus. Since then no new data were reported for this indication. In children suffering severe CVS one uncontrolled, open trial evaluating subcutaneous sumatriptan (1 to 3 mg) in 11 patients was published. Treatment was associated with a good to complete relief of symptoms in 54% of the treated episodes.

Dopamine antagonists. Parenteral dopamine antagonists (e.g., metoclopramide, chlorpromazine, prochlorperazine)
are effective abortive substances in the treatment of adult migraine and the most often used agents in the treatment of refractory migraine in pediatric EDs.\textsuperscript{41,46} Parenteral dopamine antagonists enhance migraine symptoms in two pharmacodynamic ways: in the sense of a specific antimigraine effect by interfering with the dopaminergic system and by positively influencing associated nausea and vomiting. GNG 2008 did not report on parenteral dopamine antagonists.\textsuperscript{14} By 2008, prochlorperazine was shown efficacious and safe in a randomized, controlled trial and two open-label trials demonstrating responder rates up to 85% but considerable recurrence rates (30%).\textsuperscript{45} Recently, Legault et al demonstrated efficacy and safety of metoclopramide and chlorpromazine in 184 patients suffering status migrainosus analyzed retrospectively. Recurrence rates in 1 month were 11%.\textsuperscript{47} Similarly, a retrospective chart review of 92 severe acute migraine episodes treated in the ED resulted in good efficacy and tolerability of prochlorperazine (0.15 mg/kg intravenously to a maximum of 10 mg). Treatment failure was observed in 14% of patients.\textsuperscript{48} In their prospective, open-label cohort including 64 patients, Trottier et al confirmed the excellent efficacy profile (fast pain relief) with only a low number of primary treatment failure events (need of rescue therapy in 9% of patients). However, 68% of patients reported relapse of symptoms during 7 days, which made 12% of patients return to the ED. Sixty-seven percent of relapsing patients were taking NSAIDs intended to prevent recurrence (mostly naproxen).\textsuperscript{49} Moreover, prochlorperazine aborted the symptoms in two cases of acute confusional migraine.\textsuperscript{50} Dopamine antagonists generally bear the risk of extrapyramidal symptoms (in most cases orofacial hyperkinesias and acute dystonic reactions). In adults akathisia is observed in 36 to 44%, but by coadministering diphenhydramine (0.5 mg/kg intravenously, maximum 25 mg) the incidence can be reduced to 14%. Despite the adjunctive diphenhydramine prophylaxis, 5 and 34% of patients were diagnosed as definitive and possible akathisia, respectively in the trial of Trottier et al.\textsuperscript{49} Up to this report the incidence was probably underestimated mainly due to insufficient registration. Thus, extrapyramidal symptoms can occur despite diphenhydramine prophylaxis. This side effect needs to be thoroughly discussed with the patients, and in case of acute dystonic reaction a dose of diphenhydramine (0.5 mg/kg intravenously, maximum 25 mg) is indicated and in general sufficient, even if diphenhydramine prophylaxis has been given previously.

**Dopamine antagonist in combination with NSAIDs.** The parenteral combination of a dopamine antagonist and NSAIDs is highly efficacious in the treatment of adult migraine and is increasingly prescribed in pediatrics.\textsuperscript{20,43} Kabbouche et al retrospectively rated prochlorperazine as well as metoclopramide plus ketorolac effective as 78% of 297 episodic migraineurs were pain free at discharge. Unfortunately, no data concerning recurrence rate have been reported.\textsuperscript{40}

**Dihydroergotamine.** In adults parenteral DHE was the rescue agent for aborting status migrainosus for a long time but is no longer on the markets in all countries. Based on previous data of one retrospective report of a low-dose DHE regimen GNG 2008 recommended DHE (maximum, $4 \times 0.2$ mg) as an option in emergent situations.\textsuperscript{14} In 2009, Kabbouche et al provided a pediatric high-dose protocol, retrospectively evaluated in their clinic. Patients received repeated doses of DHE ($< 25$ kg or $\leq 9$ years: 0.5 mg; $\geq 25$ kg or age $\geq 9$ years: 1 mg; every 8 hours over 3 minutes). Response was rated only after the injection of the fifth dose. If improvement was indicated, infusions were continued until headache freedom or a maximum number of 20 doses were reached. Headache freedom was achieved in 40 and 67% of 32 patients after dose 5 and doses 12 and 13, respectively. At discharge, 74% of patients were headache-free. One patient discontinued therapy due to headache worsening by dose 5, and two patients dropped out due to side effects.\textsuperscript{51} Pediatricians must be aware of the side effects of DHE (severe nausea, anxiety) that can aggravate migraine symptoms in the first instance. Therefore, comedication with antiemetics and adequate hydration are necessary. Moreover, DHE is contraindicated in pregnant females and no triptan should have been administered in the past 24 hours. Test dosing (initial injection of a half dose) is advisable, with continuation of injection after 30 minutes if test dose was well tolerated. To minimize the risk of relapse one additional dose of DHE may be administered after pain freedom is achieved.\textsuperscript{20,51}

**Valproate.** In adults parenteral VPA has been studied as a treatment option for status migrainosus with promising results.\textsuperscript{38,46} GNG 2008 described VPA (15 to 20 mg/kg in 5 minutes) as a possible alternative for status migrainosus based on limited data of one open trial.\textsuperscript{14} Since then only one case report dealing with VPA was published. A 12-year-old girl suffering acute confusional migraine responded rapidly and completely to VPA, and no recurrence was observed.\textsuperscript{52} Two VPA protocols have been reported in the literature. The first was a VPA bolus (15 to 20 mg/kg intravenously over 5 minutes) followed by an oral dose (15 to 20 mg/d) within 4 hours. The second was a parenteral VPA bolus (15 mg/kg over 5 minutes), followed by 5 mg/kg intravenously every 8 hours until headache freedom or a maximum of 10 doses was reached.\textsuperscript{53}

**Authors’ Comments on Emergency Treatment**

For the treatment of exacerbated migraine several strategies need to be discussed in the individual setting. Parenteral analgesics monotherapy can be worthy of a trial, particularly acetylsalicylic acid because it is regarded as highly effective in adults. Subcutaneous sumatriptan is an effective rescue strategy in exacerbated migraine. However, the use of oral rizatriptan offers an alternative, as differences in time to onset of action seem acceptable (10 vs. 30 minutes) and side effect profile is better. Oral application is more likely to be accepted by patients than subcutaneous injection. However, in severe episodes of CVS when there is refusal to take a tablet, subcutaneous sumatriptan may be a beneficial option. In adults a new needle-free subcutaneous application device has been approved recently, but the patient may still notice a short stitching pain. Pediatric data on this device are missing so far. Furthermore, in migraine otherwise not adequately relieved or if other agents are contraindicated parenteral dopamine antagonists are an option. However, the risk of acute
dystonic reaction has to be taken seriously, particularly in patients younger than 12 years. Despite the paucity of data, DHE should be made available for patients with otherwise intractable status migrainosus (e.g., order on behalf of an international pharmacy in specialized centers). If DHE is ineffective or contraindicated, parenteral VPA could be an alternative. After successful emergent treatment of exacerbated migraine, recurrence of symptoms is a frequent issue. Therefore, patients have to be educated and equipped with adequate outpatient treatment options. So far no regimen successfully preventing relapse has been reported in pediatrics. In adults the use of steroids for aborting refractory migraine as well as for preventing recurrence is currently discussed. For the treatment of exacerbated TTH no pediatric data are available. Parenteral analgesics, particularly acetylsalicylic acid (if not contraindicated), seem to be the most reasonable choice.

**Prophylaxis**

Up to one-third of pediatric migraineurs meet the criteria for pharmacologic prophylaxis, and several patients prone to frequent TTH or CTTH may benefit from pharmacologic prophylaxis. Antidepressants, antihypertensives, antihistamines, and antiepileptics are commonly prescribed options. However, for most of these regimens evidence is still limited and effective dose levels are rarely established. Thus, when choosing an individual preventive strategy the available evidence, extrapolated adult data, and clinical expertise should be taken into account. Currently, novel data concerning amitriptyline, propranolol, calcium-channel blockers, topiramate (TPM), and VPA are available, as well as for melatonin and the new botulinum toxin strategy. Agents not studied since 2008 are displayed in Table 5, drugs potentially beneficial for pediatric patients but only evaluated in adults so far are listed in Table 6.

**Antidepressants**

*Amitriptyline*. Amitriptyline is a second-line option in the prevention of adult migraine. GNG 2008 equally classified amitriptyline (1 mg/kg) as a drug of second choice in adolescents and in individual cases even for younger children. An open-label trial and a retrospective analysis confirmed the efficacy of amitriptyline even in lower doses (0.5 and 0.2 to 0.4 mg/kg, respectively). In the retrospective study, the responder rate was as good as under propranolol, but significantly more (tolerable) side effects were reported in the amitriptyline group. In clinical routine amitriptyline is generally well accepted by the patients, because only one dose of the retard release formulation (not the slow release formulation) is necessary and taken in the evening the side effect of mild sedation is rarely an issue. A conservative approach targets a dose of 1 to 2 mg/kg, but a lower dose (0.2–0.4 mg/kg) may also be sufficient. Due to the risk of arrhythmia an electrocardiogram should be obtained before prescription and if patients report cardiac side effects during therapy. Regarding the prevention of pediatric CTH, two former small cohort open-label trials reported efficacy of amitriptyline (1 mg/kg and 10 mg, respectively). In adult CTTH amitriptyline is one of the first-line agents.

In 2008, a consensus statement recommended amitriptyline as the first-line preventative in patients ≥ 5 years prone to CVS based on open-label trials and recall surveys reporting up to 72% responder rates. A subsequent recall survey confirmed the good efficacy profile but revealed a relevant proportion of side effects. Nevertheless, the overall profile of amitriptyline was reported to be satisfactory in CVS.

**Antihypertensives**

*Propranolol*. GNG 2008 graded the β-blocker propranolol (2 mg/kg) as a first-line option for the prophylaxis of pediatric migraine, similar to adults. As propranolol is frequently used as a comparative agent in controlled trials for migraine prevention in pediatrics, novel data from four trials are available. All four demonstrated efficacy and safety parameters in line with previous studies, even in lower doses (0.5 to 1 mg/kg). Propranolol must not be prescribed to patients with a history of atopic disease, asthma, diabetes, or heart block. Moreover, the authors do not administer propranolol to athletic patients because it may interfere with their physical activity.

*Cinnarizine*. Flunarizine (5 to 10 mg), a nonselective calcium channel blocker with selective effects on the cerebrovascular circulation, is one of the first-line agents in adult migraine prevention. Similarly, it was rated as a first-line choice for pediatric migraineurs in 2008. A recent retrospective analysis reported responder rates and tolerability parameters in line with previous findings, as did one open-label trial. Remarkably, efficacy was particularly high in patients suffering hemiplegic migraine. Because of the long half-life of flunarizine once-daily dosing is sufficient. As sedation is a commonly observed side effect, bedtime dosing is advisable. Flunarizine-associated weight gain can limit its prescription.

*Cinnarizine*. The L-type calcium channel blocker cinnarizine was shown to be effective and safe for prophylaxis in adult migraineurs. One recent randomized open-label trial demonstrated an efficacy and safety profile similar to propranolol in pediatric migraineurs.

**Antihistamines**

*Ciproheptadine*. Ciproheptadine, an antihistamine additionally exerting antiserotonergic properties, was recently considered to be possibly effective in the prevention of adult migraine by the American Academy of Neurology. In pediatrics, it has been prescribed since the 1980s. However, efficacy data are limited to one former retrospective study and one small cohort open-label trial in migraineurs younger than 12 years. Both studies reported ciproheptadine to be effective. Despite the lack of data, ciproheptadine (0.2 to 0.4 mg/kg) is regarded as the first-line option in young children (<6 years) and children unable to swallow tablets in several current reviews. Relevant side effects are sedation and weight gain due to increased appetite.

**Antiepileptics**

*Valproate*. VPA is an established first-line option in the prevention of adult migraine. GNG 2008 recommended VPA (20 to 30 mg/kg) as a third-line option emphasizing the
<table>
<thead>
<tr>
<th>Reference Indication</th>
<th>Drug (dosage)</th>
<th>Study design, number of patients (N), age of patients, and study period (SP)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>M55</td>
<td>AMT (0.5 mg/kg) CYP (0.2 mg/kg) FLU (5–10 mg) PRO (10–40 mg)</td>
<td>OL; AMT N = 21, CYP N = 17, FLU N = 19, PRO N = 20; 12.98 ± 3.11 yr; SP: 16 wk</td>
<td>Significant RMHF, RHL, RDHE, and PedMIDAS score (p &lt; 0.05) in all groups; CYP was more effective in reducing headache duration and HI than the other agents (p &lt; 0.05); AMT was more effective in reducing MHF than the other agents (p &lt; 0.05); AE: no data reported</td>
</tr>
<tr>
<td>M56</td>
<td>AMT (0.2–0.4 mg/kg) PRO (0.5–1 mg/kg)</td>
<td>RCR and follow-up interview; N = 25 first-line AMT, N = 20 second-line AMT, N = 93 PRO; 4–18 yr; SP: AMT 26 ± 15 mo, PRO 22 ± 17</td>
<td>RBHF ≥ 50%: AMT 82.2%, propranolol 85% of patients (N.S.); AE: significant more common on AMT versus propranolol (p &lt; 0.05); AMT N = 9 (weight gain, fainting, drowsiness, tremor); PRO (no hypotonia, no bradycardia, no other data reported); no dropout</td>
</tr>
<tr>
<td>CVS59</td>
<td>AMT (not specified)</td>
<td>Recall survey; N = 249; age not specified; SP: not specified</td>
<td>Relevant reduction in at least one of the outcome parameters (frequency, duration, number of emesis, severity of nausea) in 72% of patients; satisfaction with drug: 47% of patients, 62% of patients would recommend it to other patients; AE: 50% of patients (not specified); dropout of 21% of patients</td>
</tr>
<tr>
<td>M62</td>
<td>FLU (2.5–10 mg)</td>
<td>RCR and follow-up interview; N = 72; 1–17 yr; SP: 12 mo</td>
<td>RBHF ≥ 50%: 57% of all patients; 85% of hemiplegic migraine patients; AE: 21% of patients (depression, weight gain, sedation, worse headache); dropout of 16% of patients</td>
</tr>
<tr>
<td>M60</td>
<td>CIN (37.5; 50 mg) PRO (1 mg/kg)</td>
<td>ROL: N = 120 (R), N = 113 (ITT); 6–17 yr; SP: 12 wk</td>
<td>RBHF ≥ 50%: CIN 75%, PRO 72.5% of patients (N.S.); RMHF: significant in CIN and PRO (p &lt; 0.001); CIN versus PRO N.S.; secondary end points: significant RHI and RDHE in CIN and PRO (not specified); AE: CIN N = 5 (daytime sedation, irritability); PRO N = 3 (palpitation); no dropout</td>
</tr>
<tr>
<td>M61</td>
<td>sVPA (15–30 mg/kg) PRO (2–3 mg/kg)</td>
<td>RDB; N = 63 (R), N = 60 (ITT); 5–15 yr; SP: 16 wk</td>
<td>RBHF ≥ 50%: VPA 63%, PRO 83% of patients (N.S.); RMHF: significant in VPA and PRO (p &lt; 0.05); MHF after treatment: significantly lower in PRO versus VPA (p &lt; 0.01); RHDW: significant in VPA and PRO (p &lt; 0.001); AE: VPA N = 11 (abdominal pain, drowsiness, weight gain), PRO N = 3 (vertigo, insomnia); no dropout</td>
</tr>
<tr>
<td>M55</td>
<td>sDVPA (1,000 mg)</td>
<td>OL; N = 112; 12–18 yr; SP: 12 mo</td>
<td>Adherence ≥ 6 mo: 74%; ≥ 12 mo: 47%; reason of dropout: AE 13%, lacking efficacy 10%, lost 10.9%; compliance ≥ 70%; 68% efficacy: sustained RMHF of 50% over SP; AE: weight gain, nausea, somnolence, upper respiratory tract infection, increased ammonia, sinusitis reported in ≥ 10% of patients; SAE: N = 5, 1 possibly related (hyperammonemia), 1 probably not related (peptic ulcer)</td>
</tr>
<tr>
<td>M64</td>
<td>sDVPA (250–1,000 mg)</td>
<td>OL; N = 241, N = 236 (ITT); 12–18 yr; SP: 12 mo</td>
<td>Adherence ≥ 6 mo: 64%; ≥ 12 mo: 40%; reason of dropout: AE 17%, lost 13%; withdrawn consent 12%, noncompliance 10%; compliance ≥ 70%; 54% efficacy: RMHF of 75% between 1st and 4th month, sustained effect over SP; AE: nausea, vomiting, weight gain, nasopharyngitis, migraine, upper respiratory tract infection reported in ≥ 10% of patients; SAE: N = 10, 3 probably not related (depression, impulse-control disorder)</td>
</tr>
<tr>
<td>M66</td>
<td>sVPA (15 mg/kg) TPM (2 mg/kg)</td>
<td>RCR; VPA N = 20; 11 ± 1.65 yr, TPM N = 28; 10.35 ± 2.03 yr; SP: not specified</td>
<td>RMHF: significant in VPA, TPM; RHI: significant in VPA, TPM; RDHE: significant in VPA, TPM; PedMIDAS: significant in VPA, TPM; all parameters (p &lt; 0.05 or 0.01); AE: VPA N = 2 (raised liver transaminases, drowsiness); TPM N = 4 (nausea, mood change, weight loss, weakness); no dropout</td>
</tr>
<tr>
<td>CVS67</td>
<td>VPA (10–40 mg/kg)</td>
<td>OL; N = 13; 3–10 yr; SP: 2 wk to 8 yr</td>
<td>Relevant reduction of frequency in 85% of patients; complete resolution N = 2; marked improvement N = 9; treatment failure N = 2; AE: none</td>
</tr>
<tr>
<td>CDH68</td>
<td>VPA (1,000 mg)</td>
<td>RDBPC; N = 70 (CM N = 29; CTT H N = 41); 14–76 yr; SP: 12 wk</td>
<td>CM: significant reduction in general pain level (p &lt; 0.05), maximum pain level and pain frequency (p &lt; 0.01); CTH: significant reduction in pain frequency (p &lt; 0.001); AE: VPA N = 3 (somnolence, tremor, impotence, heart loss) 3 dropouts; placebo N = 1 (dizziness, nausea), 1 dropout</td>
</tr>
<tr>
<td>M69</td>
<td>TPM (50–200 mg)</td>
<td>RCR; N = 37; 7–20 yr; SP: 12 ± 5 mo</td>
<td>RBHF ≥ 50%: 76% of patients; RMHF: significant (p &lt; 0.001); AE: N = 10 (cognitive decline, drowsiness, paresthesia, anhidrosis), 10 dropouts 7 A (cognitive issues, paresthesia, anhidrosis); 3 lack of efficacy</td>
</tr>
<tr>
<td>M70</td>
<td>TPM (50 mg; 100 mg)</td>
<td>RDBPC; N = 106 (R), N = 103 (ITT); 12–17 yr; SP: 16 wk</td>
<td>RMHF: TPM 100 versus placebo significant (p &lt; 0.05); TPM 50 versus placebo not significant; RBHF ≥ 50%: TPM 100 83%, placebo 45% (p &lt; 0.01); TPM 50 versus placebo not significant; AE: TPM 74%, placebo 48% of patients; more common in TPM; upper respiratory tract infection, pneumonia, anorexia; 6 dropouts (TPM 100 N = 2 (fatigue, renal calculi); TPM 50 N = 3 (fatigue, nervousness, headache/emotional liability/depression) placebo N = 1 (hypokalemia)</td>
</tr>
<tr>
<td>M; CTTH71</td>
<td>Melatonin (3 mg)</td>
<td>OL; N = 22 (migraine N = 14, CTT H N = 8); 6–16 yr; SP: 12 wk</td>
<td>RBHF ≥ 50%: 14/21 patients (migraine N = 10, CTT H N = 4) AE: N = 1 (excessive daytime sleepiness), dropout of 1 patient</td>
</tr>
<tr>
<td>CM73</td>
<td>Olanzapine (75–200 units)</td>
<td>RCR; N = 45; 16.8 ± 2.0 yr; SP: interval 2 mo, evaluation before second and third intervention</td>
<td>RMHF: significant (p &lt; 0.01); RHI: no change; change from severe to moderate disability in PedMIDAS (N.S.); AE: N = 8 (pain at injection site, eyelid infection, eyelid pain, swelling of left eyebrow, neck/shoulder myalgia); no dropout</td>
</tr>
</tbody>
</table>
### Table 8 (Continued)

<table>
<thead>
<tr>
<th>Reference Indication</th>
<th>Drug (dosage)</th>
<th>Study design, number of patients (N), age of patients, and study period (SP)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDH14</td>
<td>OnA (100 units)</td>
<td>RCR; N = 10 (CM N = 5, new onset DH N = 2, CTH N = 2, trocheol neuralgia N = 1); 11–17 yr; SP: 1–3 injections, interval 3 mo</td>
<td>Headache relief of clinical importance: 4/10 (CM N = 3/5); AE: N = 3 (flu-like symptoms, brachial paresthesia), no dropout</td>
</tr>
<tr>
<td>CDH17</td>
<td>OnA (100 units)</td>
<td>RCR; N = 12 (long-term treatment [LIT] N = 6; CM N = 2; CDH + M N = 4); 14–18 yr; SP: 3–29 mo, interval 3 mo</td>
<td>RHI: 6/6 LIT, complete relief 2/6; improvement of quality of life: 6/6 LIT; good response after first injection, further data missing: N = 4; no improvement after first injection, treatment not continued: N = 2; AE: N = 4 (ptosis, blurred vision, hematoma at injection site with tingling in one arm, burning sensation at injection site)</td>
</tr>
<tr>
<td>CDH18</td>
<td>OnA (20–90 units)</td>
<td>RCR and follow-up interview after 10 yr; N = 5 (N = 1 lost to follow-up); 10–16 yr; SP: 1–4 injections, mean interval 2.7 mo</td>
<td>Short-term effect: relevant RMHF and RHI in 5/5 patients; long-term: 0/4 patients reported CDH; 4/4 patients rated the intervention as pivotal, decisive or helpful; AE: none</td>
</tr>
</tbody>
</table>

**Abbreviations:** AMT, amitriptyline; CDH, chronic daily headache; CIN, cinnarizine; CM, chronic migraine; CTH, chronic tension-type headache; CVS, cyclic vomiting syndrome; CYP, cyproheptadine; FLU, flunarizine; ITT, intention to treat; kg, kilogram body weight; M, migraine; N.S., nonsignificant; OL, open-label trial; OnA, onabotulinumtoxin A; PedMIDAS, pediatric migraine disability score; PRO, propranolol; R, randomized; RBHF, reduction in headache frequency; RCR, retrospective chart review; RDB, randomized, double-blind trial; RDBPC, randomized, double-blind, placebo-controlled trial; RHDW, reduction in headache duration per week; (R)DHE, (reduction in) duration of headache episode; (R)HI, (reduction in) headache intensity; (R)MHE, (reduction in) monthly headache frequency; s(D)VPA, sodium (d)ivalproate; (S)AE, (serious) adverse event; TPM, topiramate.

importance of respecting the contraindications, as pediatric data have been inconclusive. Since 2008, four trials addressing pediatric migraine prevention with VPA have been published. In a randomized, double-blind trial VPA was rated as effective and safe as propranolol, but the primary outcome measure (reduction in baseline headache frequency > 50%) favored propranolol. Sustained long-term efficacy up to 12 months was demonstrated in two open-label trials. Interestingly, reduction in headache frequency was reported to be relevant only from the 4th month of treatment. Finally, one retrospective study reported effectiveness of VPA in reducing frequency, intensity, and duration of attacks as well as in overall disability. Tolerability profiles reported were similar to the data of previous trials and overall rated as “good.” However, in the long-term studies increased ammonia levels were commonly observed, peaking > 90 μmol/L in about 20% of subjects at least once during the study period. In most cases hyperammonemia was only transient, but these findings emphasize the importance of thorough surveillance and education about symptoms of hyperammonemia of patients on long-term VPA. Moreover, VPA contraindications need to be excluded before the start of treatment, and the risk of teratogenicity and fertility-related side effects have to be discussed with teenage patients. As the adverse effects seem to be dose dependent, a target dose of 15 to 20 mg/kg (maximum 100 mg) could be reasonable. Overall, particularly overweight patients and patients with epilepsy may benefit from TPM. In prevention of CTHH pediatric data concerning TPM are limited to one former small recall survey that reported TPM (15 to 100 mg) to be effective. In adult CTHH, TPM is an agent of further choice.

**Others**

**Melatonin.** Limited evidence for the effectiveness of melatonin in the prevention of adult headache exists. One small trial reported efficacy in pediatric migraine and CTHH patients.

**Onabotulinumtoxin A (OnA).** OnA was approved for the prevention of adult chronic migraine in 2010 by the FDA and in 2011 by European authorities. Pediatric data are limited to three retrospective studies and one retrospective case series with long-term follow-up showing promising effects and a good tolerability profile in several patients suffering chronic primary headache.

**Authors’ Comments on Prophylaxis**

In general, the authors propagate a defensive much more than an offensive strategy regarding pharmacoprophylaxis. First, nonpharmacologic measures should be established. These include lifestyle modification, regular exercise, stress relaxation, biobehavioral and psychotherapeutic intervention, and complementary measures. In general, pharmacologic prophylaxis is only indicated if those actions have been ineffective or insufficient. In the authors’ opinion, some patients may benefit from a multimodal regimen in the beginning, in particular the severely disabled or those at risk for chronic disease. For example, pharmacologic prevention may bridge time until a consistent response to behavioral therapy is achieved. For the prevention of pediatric migraine, cinnarizine, propranolol, and amitriptyline are established options. Flunarizine is particularly beneficial in patients prone to hemiplegic migraine. TPM is widely used, but tolerability, side effect profile, and
contraindications have to be discussed. Acetylsalicylic acid can be an alternative in adolescents, although increased risk of bleeding may be a relative contraindication. The use of cypriproheptadine is often cited in younger children, but due to limited evidence and lack of our own experience the authors cannot recommend it. VPA does not seem to be a reasonable choice for the long-term treatment due to its side effect profile. The value of cinnarizine and melatonin as well as zonisamide in the prophylaxis of pediatric migraine should be further evaluated in controlled trials. For gapapentin pediatric data are missing. Botulinum toxin remains an experimental option in the younger population. Injection regimens have to be adapted and controlled studies have to be launched. Despite these restrictions, botulinum toxin can be regarded as a reserve option in severely disabled patients with chronic primary headache who experience treatment resistance to other (at least two) agents, including multimodality. If and to what extent the so-called (active) muscular trigger points are a sufficient and guiding concept for this new treatment option when transferred to adolescents and even children is speculative. All other agents have fairly been systematically investigated regarding prevention of pediatric chronic migraine, CTH, and chronic daily headache so far. Hence, the use of the above-mentioned preventatives, particularly amitriptyline and TPM, should be taken into consideration. For the use of mirtazapine and tizanidine in pediatric CTH, no data are currently available. Patients suffering from migraine could benefit from amitriptyline or, assuming a thorough risk-to-benefit analysis, VPA.

Discussion

Primary headaches are a common health issue in children and adolescents. Adequate therapy undoubtedly must be guaranteed, not only to improve the current health status of the patients but also to prevent progress to chronic disease in adulthood. High-quality evidence for the pharmacologic treatment of pediatric primary headaches is still fairly limited, but advances can be reported, particularly regarding the symptomatic treatment of migraine with triptans. However, today only a minority of pediatric migraineurs receives migraine-specific outpatient treatment. With the new data available and the coherent approval modifications by the FDA and EMA taken into account, the use of triptans should no longer be generally denied to children and adolescents. Agents as effective and safe as triptans should be available to both adult AND pediatric patients. Migraine-specific agents such as triptans may have advantages in the long run that are not yet known compared with unspecific drugs such as analgesics (i.e., long-term outcome or modification of condition). Another issue is the emergent treatment of exacerbated migraine. Some pediatricians tend to hesitate or refuse to use currently available potentially effective agents. In this context, an Australian audit reported emergent treatment to be markedly delayed (median, 2 hours) even though the average interval between onset of migraine and visit to the ED was $\geq$2 days. Moreover, despite treatment resistance experienced with their recommended outpatient regimen, only about 60% of ED patients receive a treatment in line with the limited available evidence (dopamine antagonists, analgesics, NSAIDs, triptans, DHE) and only a few patients receive migraine-specific agents (triptans, 0.5 to 1%; DHE, 0.9%) at all. Because early aggressive treatment is the key to preventing disability and allodynia, these numbers are not acceptable. Patients suffering exacerbated migraine should be treated in a satisfying manner by applying existing options. Concerning preventive pharmacologic therapy of migraine, about one-third of adolescents meet the criteria, although only 10 to 19% are offered prophylaxis. Efforts to make effective prophylactics available to all patients are evidently necessary. Also, novel prevention options with reasonable safety profiles must not be generally denied to children and adolescents, because they may imply an important benefit in the long term, taking into account the putative mechanisms of action.

Even with the progress of the last years, appropriate treatment of primary headaches still remains an unmet medical need in pediatric medicine. Several factors contribute to the paucity of reliable data for migraine. First, in pediatric trials, an age-dependent high placebo response rate is an issue, to some extent attributed to the generally shorter duration of acute attacks. Depending on the study design, the placebo rate can be 69% in acute and 55% in preventive treatment, respectively. Therefore, the proof of superiority over placebo is difficult to supply and requires a complex study design and adequately powered trials. Second, the classification of pediatric patients in the line with IHS criteria may not always be appropriate. Pediatric study populations may tend to be more heterogeneous due to the high prevalence of mixed-type headache. Third, study periods, end points and assessment instruments may not be equally suitable for all age groups with respect to the natural evolution of the condition. Most of these factors could also be transferred to the issue of pediatric TTH trials, a field even less investigated. In this context, another issue in pediatric headaches should be mentioned. The IHS classification is barely suitable for numerous pediatric patients from the clinical point of view because the frequent mixed-type headache is not sufficiently addressed. In those patients, individually tailored treatment strategies should focus on the most current complaints.

All the above-named factors should be considered in future pediatric headache research. Issues to be principally addressed include the following:

- Controlled (head-to-head) comparison of efficacy and safety profiles of different drugs and their formulations, respectively
- Detailed investigation of the complex properties of several agents in migraine (e.g., triptans, dopamine antagonists)
- Long-term efficacy and safety profiles of agents, including the transition period to adulthood
- Effective strategies to prevent relapse after successful treatment of acute exacerbated migraine
• Controlled studies assessing multimodality (including pharmacotherapy) as the proclaimed treatment option

Conclusion
Pharmacotherapy of primary headaches is a medical field appropriate for practicing personalized medicine. A variety of agents is available, and the team of patient, parents, and physician (and psychologist) needs to decide on the best treatment strategy by taking into account the different properties of available drugs. Drug profiles are complex and demand a well-considered and thorough handling. However, they allow the same full range of individualization in children and adolescents as in adults. Because profiles of many agents differ only slightly or even overlap, a hierarchical grading of their use seems inappropriate, particularly considering the limited pediatric evidence available to most of them. As often in pediatric pharmacotherapy, off-label use of drugs is the norm in almost all settings of headache treatment. In addition to over-the-counter analgesics, only four triptans for acute migraine and flupirtine for acute TTH have been approved by different regulatory authorities. For the prevention of pediatric primary headache no agent has been approved so far. Thus, the treatment of pediatric primary headaches remains an unmet medical need, and further research is definitely necessary.

References
18 Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol 2010;9(2):190–204
30 Lewis DW. Almotriptan for the acute treatment of adolescent migraine. Expert Opin Pharmacother 2010;11(14):2431–2436
32 Kakisaka Y, Wakisawa K, Sato I, et al. Successful treatment with sumatriptan in a case with cyclic vomiting syndrome
combined with 18q- syndrome. J Child Neurol 2009;24(12):1561–1563

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


